Salvage therapy with brentuximab vedotin has demonstrated promising results in phase 2 trials in real-world settings in treating patients with CD30-positive classical Hodgkin lymphoma (HL). The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.